Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

TO THE EDITOR:

AL amyloidosis is a rare condition characterized by the deposition of misfolded immunoglobulin light chains produced by clonal plasma cells or lymphoplasmacytic cells. Treatment aims at reducing the production of pathogenic free light chains (FLCs) to prevent organ damage. Deep and sustained hematologic response (HemR) correlates with organ function improvement and with survival outcomes.¹ Current guidelines recommend a regimen containing daratumumab, bortezomib, cyclophosphamide, and dexamethasone² for patients with newly diagnosed AL amyloidosis. Although this treatment results in high response rates,³ a proportion of patients are refractory or eventually relapse. The use of immunomodulatory drugs (IMiDs) or carfilzomib can be hampered by kidney injury or cardiovascular issues. Hence, new treatment options for patients with relapsed or refractory (R/R)...